Search clinical trials for: Early access program

Total 31262 results

AstraZeneca
CernerEnviza / Oracle

Recruiting

Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs. (ERYTHRO)

Systemic Lupus Erythematosus

United Kingdom, Portugal, Israel, France, Greece, Spain, Italy
Mantis Photonics AB
Blekinge County Council Hospital; Blekinge Institute of Technology

Not yet recruiting

Hyperspectral Retinal Observations for the Cross-sectional Detection of Alzheimer's Disease

Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset

Sweden
Eli Lilly and Company

Recruiting

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)

Breast Neoplasms

China, Japan, United States, Australia, Taiwan, Belgium, Canada, United Kingdom, Spain, France, Argentina, Ireland, Netherlands, Turkey, Czechia, Korea, Republic of, Finland, Hungary, Italy, Mexico, Brazil, Germany, India, Austria, Greece, Roman... and more
Mathematica Policy Research, Inc.
Boston Children's Hospital; Department of Health and Human Services

Not yet recruiting

Head Start REACH: Strengthening Outreach, Recruitment and Engagement Approaches With Families (HSREACH)

Early Intervention, Educational (Head Start and Early Head Start Access and Participation)

United States
Astellas Pharma Global Development, Inc.

Available

Early Access Program for Zolbetuximab

Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma Cancer | Metastatic Gastric Adenocarcinoma Cancer

United States, Germany
Ionis Pharmaceuticals, Inc.

Available

Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia Syndrome
Aziende Chimiche Riunite Angelini Francesco S.p.A
Hippocrates Research

Completed

This is a Retrospective Study on the Use of CENOBAMATE as Adjunctive Treatment in Patients Suffering From Epilepsy in Early Access Program in Germany, France and UK (CENOR)

Epilepsy | Focal Onset Seizure

United Kingdom, France, Germany
Novartis Pharmaceuticals

Available

Global Managed Access Program Cohort for Remibrutinib in Adult Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria
Merus N.V.

Available

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Renal Cell Carcinoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Solid Tumor, Unspecified, Adult | Unknown Primary Tumors | NRG1 Fusion
Alexion Pharmaceuticals, Inc.

Available

Danicopan Early Access Program

Paroxysmal Nocturnal Hemoglobinuria | PNH | Extravascular Hemolysis
Nova Scotia Health Authority
Queen Elizabeth II Health Sciences Centre Foundation; Research Nova Scotia; Killam...

Completed

Psychotherapy for Psychosis, Adverse Events, and Substance Misuse

Psychotic Disorders | Stress Disorders, Traumatic | Substance Use

Canada
ZevraDenmark

Available

Early Access Program With Arimoclomol in US Patients With NPC

Niemann-Pick Disease, Type C

United States
MaaT Pharma

Available

Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease (ATLAS)

Acute Graft Versus Host Disease in Intestine | Steroid Refractory GVHD

France
Shionogi

Completed

Use of Cefiderocol in the Management of Gram-Negative Infections (PERSEUS)

Gram-Negative Infection

Spain
Genmab
AbbVie

Approved for marketing

Expanded Access Program for Epcoritamab

Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-cell Lymphoma (HGBCL) | Grade 3B Follicular Lymphoma
Alexion

No longer available

Early Access Program for ALXN1840 in Patients With Wilson Disease

Wilson Disease
AstraZeneca

Approved for marketing

Himalaya Early Access Program

Unresectable Hepatocellular Carcinoma

United States
Ferrer Internacional S.A.

Available

Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease

Pulmonary Hypertension | Interstitial Lung Disease | Combined Pulmonary Fibrosis and Emphysema
Florida International University
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Advancing Child Competencies by Extending Supported Services (ACCESS) for Families Program (ACCESS)

Developmental Delay | Disruptive Behavior

United States
Bristol-Myers Squibb

Completed

A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom

Esophageal Squamous Cell Carcinoma

United Kingdom
Yuhan Corporation

Approved for marketing

Early Access Program of Lazertinib in Republic of Korea

Lung Cancer
ElsaLys Biotech

Available

Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease

Steroid Resistant Acute Graft Versus Host Disease

France
Akcea Therapeutics
CaligorRx, Inc.

No longer available

Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia
AstraZeneca
Clinigen, Inc.

No longer available

Anifrolumab Early Access Program (AMANA)

Systemic Lupus Erythematosus
Janssen Research & Development, LLC

No longer available

An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease

Crohn Disease

Brazil
Impatients N.V. trading as myTomorrows
Kamada, Ltd.

No longer available

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

Alpha 1-Antitrypsin Deficiency | Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Steroid Refractory Acute Graft Versus Host Disease | Alpha-1 Proteinase Inhibitor | Alpha-1 Protease Inhibitor Deficiency | Acute Graft-Versus-Host Reaction Following Bone Marrow...
Blueprint Medicines Corporation

Approved for marketing

Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

GIST
AstraZeneca

Approved for marketing

An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia (MOXE)

Relapsed/Refractory Hairy Cell Leukemia
BELEN RUIZ-ANTORAN

Completed

Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine (KNOWHER)

Breast Neoplasms

Spain
Instituto Nacional de Ciencias Medicas y Nutricion...
Global Cancer Institute

Completed

A Patient Navigation Program to Increase Access to Early Supportive Care in Patients With Stage IV Solid Tumors

Neoplasm Metastasis

Mexico
Hoffmann-La Roche

Completed

A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) (MELANIS)

Melanoma

France
Janssen Research & Development, LLC

No longer available

A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Prostate Neoplasms

Brazil
Astellas Pharma Global Development, Inc.

No longer available

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

Australia, Italy, United Kingdom
Bayer

Completed

Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program

Carcinoma, Renal Cell

Japan
Dana-Farber Cancer Institute
Bristol-Myers Squibb

No longer available

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse

United States
Janssen-Cilag Farmaceutica Ltda.

Approved for marketing

Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

B-cell Chronic Lymphocytic Leukemia

Brazil
Bristol-Myers Squibb

No longer available

Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program

Hepatitis B | Chronic Disease

Israel
Janssen-Cilag International NV

No longer available

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Hepatitis C

Australia, Belgium, Germany, Spain, Switzerland, Romania, Serbia, Greece, New Zealand, Brazil, Russian Federation, Austria, Hungary, Czech Republic, Luxembourg
Tibotec Pharmaceuticals, Ireland

Completed

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

HIV-1

United States, Belgium, Germany, Taiwan, Spain, Mexico, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Korea, Republic of, Russian Federation, Puerto Rico, Luxembourg
Tibotec Pharmaceuticals, Ireland

Approved for marketing

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

HIV Infections

United States, Belgium, Germany, Taiwan, Spain, Switzerland, Mexico, Slovenia, Malaysia, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Russian Federation, Czech Republic, Puerto Rico, Thailand, Hungary, Luxembourg, Venezuela
Celgene Corporation

Completed

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Germany
Bristol-Myers Squibb

No longer available

Atazanavir for HIV Infected Individuals: An Early Access Program

HIV Infections

United States, Puerto Rico
Stanford University
California Breast Cancer Research Program

Completed

Expanding Rural Access: Distance Delivery of Support Groups (Main Study)

Depression | Breast Cancer | Stress | Breast Cancer Non-invasive Breast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer Metastatic Breast Cancer

United States
Abbott

Approved for marketing

Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis (ReAct)

Rheumatoid Arthritis
National Institute of Allergy and Infectious Diseases...

Completed

Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection

HIV Infections

United States
Indiana University
Academic Model Providing Access to Healthcare (AMPATH)

Not yet recruiting

A Cervical Cancer Prevention Program Kenya: Overcoming Obstacles to Care, Promoting Understanding of HPV Natural History (Merck-3)

Cervical Cancer | Cervical Cancer Prevention
Nova Scotia Health Authority
Queen Elizabeth II Health Sciences Centre

Not yet recruiting

Evaluation of a Brief Intervention to Improve Engagement in Early Intervention Services for Psychosis

Psychotic Disorders | Engagement, Patient | Psychiatric Hospitalization

Canada
Fudan University

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer (QUEEN-Dream)

Neoadjuvant Therapy | Early Breast Cancer | TNBC, Triple Negative Breast Cancer

China
Fudan University

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer (QUEEN-Neo)

Neoadjuvant Therapy | Early Breast Cancer | HR+HER2- Breast Cancer
Centre for Interdisciplinary Research in Rehabilitation...
Jewish General Hospital

Not yet recruiting

Early Mobilization in Cardiovascular Units

Cardiovascular Diseases

Canada

Search clinical trials for: Early access program

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations